Centrifuge and separate serum
Centrifuge and separate serum
2 days at 4ºC, 2 months at -20ºC
DHAS a weak androgenic that plays an important role in the development of male secondary sexual characteristics at puberty. It can metabolize to more potent androgens like androstenedione and testosterone, and thus be an indirect cause of hirsutism or virilisation. DHEAS is measured to evaluate adrenal function and to investigate causes of virilisation, hirsutism, alopecia in women or polycystic ovary syndrome (PCOS). It is also of value in the specialist assessment of disorders of sex development, such as in the assessment of ambiguous genitalia, or of adrenarche and delayed/precocious puberty. DHEAS concentrations are normally high in both male and female newborns. They drop sharply shortly after birth, then rise again during puberty. DHEAS concentrations peak between the ages of 18 to 30 years and then slowly decline with age.
None. Sample can be collected any time of day.
DHAS is a weak androgen derived by conversion of intermediate steroid hormones in the adrenal cortex. It is the principle androgen secreted by the adrenal and is the most abundant steroid hormone in the body. DHAS levels are age dependant and increase at puberty. In men, some DHAS may derive from the testes, partly accounting for the sex difference which emerges at about age 15. This hormone is not produced by the ovaries even under pathological conditions. In itself DHAS is only weakly androgenic, but it can metabolize to more potent androgens like androstenedione and testosterone. DHAS exhibits no significant diurnal variation, or dependence on sex-hormone binding globulin concentrations. Its abundance, together with its within-day and day-to-day stability, makes it an excellent direct indicator of adrenal androgen output.
Please contact the duty biochemist for age/sex related reference ranges/ 0121 371 6543
NEQAS
Copyright UHB Pathology 2018
Protection of Personal Information – Clinical Laboratory Services comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
University Hospitals Birmingham medical laboratories at Queen Elizabeth Hospital, Heartlands Hospital, Good Hope Hospital and Solihull Hospital are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://qehbpathology.uk/test-database
For further information contact Louise Fallon, Quality Manager, 0121 371 5962